NKTR-214 (also called Bempegaldesleukin) is an experimental immunotherapy treatment. NKTR-214 is similar to a naturally occurring compound in the body called IL-2 that is produced by white blood cells to increase the growth and activity of other white blood cells – thus strengthening the immune response against cancer cells.
In the trial, this drug will be tested in combination with two Health Canada-approved anti-cancer therapies in a so-called “triplet combination”: Nivolumab (Opdivo®) and Axitinib (Inlyta®).
Nivolumab is already approved for the treatment of Kidney Cancer and targets a molecule called PD-1. Blocking PD-1 helps to prime the body’s immune defences in order to target and destroy cancer cells.
Axitinib is also approved for the treatment of Kidney Caner and works by blocking a molecule called VEGFR to prevent cancerous tumours from growing new blood vessels.
This study will have two treatment groups that will be randomly assigned upon your enrollment in the trial:
Group 1: Triplet combination of NKTR-214 + Nivolumab + Axitinib
Group 2: Doublet combination of Nivolumab + Axitinib
In order to maximize effectiveness and minimize side effects, different doses of each drug may be used to determine the optimal dosage of these medications.
There is no control group in the study, so there will be no “placebo”, and all patients will receive some form of treatment.
- Clear cell kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- No prior drug therapy is permitted
Additional eligibility criteria will apply. Please speak to your doctor.Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBC Cancer||Principal InvestigatorDr. Christian Kollmannsberger||LocationVancouver, BC||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr. Aaron Hansen||LocationToronto, ON||Trial StatusRecruiting|